New lncRNA Drives Cisplatin Resistance in Lung Cancer
BIOENGINEER.ORG
New lncRNA Drives Cisplatin Resistance in Lung Cancer
In an unprecedented breakthrough, researchers have uncovered a revolutionary molecular mechanism behind chemoresistance in non-small cell lung canc...
Gut Microbial Ξ²-Glucuronidases Drive Colorectal Cancer
BIOENGINEER.ORG
Gut Microbial Ξ²-Glucuronidases Drive Colorectal Cancer
In a groundbreaking study published in Nature Communications, researchers have unveiled the profound influence of gut microbial Ξ²-glucuronidases o...
Licence to kill cancer: $17m boost to supercharge β€˜spy’ cells
WEHI
License to kill cancer: $17m boost to supercharge β€˜spy’ cells
A bold plan to supercharge immune cell β€˜spies’ to better seek out and kill cancer cells has received a $17 million funding boost from the Austr...
What if RFK Jr. reacted to his cousin's terminal cancer as JFK reacted to his baby's death?
STAT
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
When President Kennedy’s newborn son died in 1963, it galvanized research. A new Kennedy family tragedy should spur RFK Jr. to support cancer res...
NKX3.1 and AURKA Deregulation in Prostate Cancer
BIOENGINEER.ORG
NKX3.1 and AURKA Deregulation in Prostate Cancer
In recent advancements in cancer research, significant attention has been focused on the intricate relationship between NKX3.1 and AURKA, especiall...
Intratumoral cancer therapy market set to grow sharply through 2033 https://www.thepharmaletter.com/pharmaceutical/intratumoral-cancer-therapy-market-set-to-grow-sharply-through-2033
New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
The Jerusalem Post | JPost.com
PHAROS regimen shows major gain for lung cancer patients | The Jerusalem Post
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at...
Keratinocyte Genetic Evolution Drives Skin Cancer Development
BIOENGINEER.ORG
Keratinocyte Genetic Evolution Drives Skin Cancer Development
In an extraordinary leap forward in cancer biology, recent research has unraveled the intricate genetic evolution of keratinocytes as they transfor...
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results https://www.fool.com/coverage/filings/2025/11/27/this-fund-bought-usd38-million-of-celcuity-as-stock-surges-on-investigational-cancer-drug-results/
Coffee Intake Reduces Liver Cancer Risk https://www.emjreviews.com/hepatology/news/coffee-intake-reduces-liver-cancer-risk/